[Comparative effects of ricinoleic acid and senna on orocecal and oroanal transit time in healthy subjects. Application of the salacylazosulfapyridine method]
- PMID: 1347025
[Comparative effects of ricinoleic acid and senna on orocecal and oroanal transit time in healthy subjects. Application of the salacylazosulfapyridine method]
Abstract
The appearance in plasma of sulphapyridine after oral administration of salicylazosulphapyridine (Salazopyrin) was shown to be useful for measuring the orocecal transit time in normal subjects. The purpose of this study was to use this method in diarrhea with accelerated intestinal transit time. A two-step study was performed in 12 healthy volunteers: a) under resting conditions; b) 2 weeks later with ricinoleic acid 40 ml (n = 6) or senna 19 mg (X-Prep = 1.2 g; n = 6) administration. In each step, Salazopyrin (2 g) and 20 radiopaque markers were ingested with a 200 kcal meal (Polydiet TCM = 200 ml). The following parameters were determined: a) plasmatic level of sulphapyridine (spectrophotometry) at 30 min intervals during 12 h; b) 2-day stool frequency and weight; c) oro-anal transit time (passage of the first marker and half of the markers in stools). In one subject, no sulphapyridine level was detected after administration of ricinoleic acid. With senna, 2 day stool frequency and weight increased by 80 and 131 percent respectively: orocecal transit time decreased from 6.1 +/- 1.3 to 4.8 +/- 1.2 h (m +/- SD; P less than 0.01) and oro-anal transit time (first marker) decreased from 31.8 +/- 9.6 to 20.7 +/- 8.9 (P less than 0.05). With ricinoleic acid, 2 day stool frequency and weight increased by 212 and 350 percent respectively; orocecal transit time decreased from 5.8 +/- 1.8 to 2.2 +/- 0.7 (P less than 0.01) and oroanal transit time (first marker) decreased from 25.3 +/- 7.1 to 8.0 +/- 6.8 h (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
The variability of orocecal transit time evaluated by the salicylazosulphapyridine/sulphapyridine method.Int J Clin Pharmacol Ther Toxicol. 1991 Apr;29(4):147-50. Int J Clin Pharmacol Ther Toxicol. 1991. PMID: 1676990
-
Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake.Clin Pharmacol Ther. 1995 Apr;57(4):461-70. doi: 10.1016/0009-9236(95)90217-1. Clin Pharmacol Ther. 1995. PMID: 7712676 Clinical Trial.
-
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.Gastroenterology. 2007 Sep;133(3):761-8. doi: 10.1053/j.gastro.2007.06.067. Epub 2007 Jul 3. Gastroenterology. 2007. PMID: 17854590 Clinical Trial.
-
Effects of cilomilast, a selective phosphodiesterase 4 inhibitor, on esophageal motility and pH, and orocecal and colonic transit: two single-center, randomized, double-blind, placebo-controlled, two-part crossover studies in healthy volunteers.Clin Ther. 2006 Apr;28(4):569-81. doi: 10.1016/j.clinthera.2006.04.003. Clin Ther. 2006. PMID: 16750468 Clinical Trial.
-
The influence of telenzepine on gastrointestinal transit: comparison with placebo and domperidone.Z Gastroenterol. 1990 Feb;28(2):85-9. Z Gastroenterol. 1990. PMID: 2181787 Clinical Trial.
Cited by
-
Effects of different levels of ergot in concentrate on the health and performance of male calves.Mycotoxin Res. 2007 Mar;23(1):43-55. doi: 10.1007/BF02946024. Mycotoxin Res. 2007. PMID: 23605816
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous